Plain-English translation of ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called STEAP1 CART, which uses your own immune cells specially trained to attack prostate cancer cells. The treatment will be combined with , a hormone therapy medication you may already be familiar with. The goal is to see if this combination can help men whose prostate cancer has continued to grow despite previous treatments.
Advanced prostate cancer often stops responding to standard hormone therapies over time, leaving patients with limited options. This trial is exploring whether training immune cells to target cancer cells and combining them with existing medication might help patients whose cancer has become resistant to other treatments.
You likely qualify if…
You likely don't qualify if…
First, you'll have white blood cells collected from your blood in a procedure called leukapheresis. Then you'll receive two chemotherapy medications to prepare your body, followed by an infusion of your specially trained immune cells on day zero. You may also take the hormone medication by mouth starting on day zero and continuing daily. Throughout the study, you'll have regular blood tests, imaging scans (CT, MRI, or PET), and tumor biopsies to monitor how well the treatment is working. Follow-up visits are scheduled at 2, 3, 4, 5, 6, 9, and 12 months, then every 6 months for up to 5 years, and then yearly through year 15.
AI-generated summary from trial data · Aug 25, 2026 · Not medical advice
United States